Veru (NASDAQ:VERU) PT raised to $31.00 at Brookline Capital Management


Veru (NASDAQ:VERU – Get a Rating) saw its price target raised by stock analysts Brookline Capital Management from $29.00 to $31.00 in a report on Wednesday, reports The Fly. The company currently has a “buy” rating on the stock. Brookline Capital Management’s price target suggests a potential upside of 116.33% from the company’s previous close.

A number of other stock analysts also weighed in on VERU. TheStreet upgraded Veru’s shares from a ‘d+’ rating to a ‘c’ rating in a Friday, April 29 research report. Oppenheimer raised his price target on Veru shares from $25.00 to $36.00 and gave the stock an “outperform” rating in a Tuesday, April 12 research report. Jefferies Financial Group raised its price target on Veru shares from $33.00 to $55.00 in a Friday, May 13 report. Cantor Fitzgerald reissued an “overweight” rating on Veru shares in a Friday, May 13 report. Finally, Zacks Investment Research downgraded Veru shares from a “buy” rating to a “hold” rating in a Thursday, April 21 report. One research analyst has rated the stock with a hold rating and four have assigned the company’s stock a buy rating. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.40.

NASDAQ:VERU traded at $1.27 on Wednesday, hitting $14.33. 465,774 shares of the company were traded, against an average volume of 22,628,762. The company has a market capitalization of $1.15 billion, a price-earnings ratio of -41.97 and a beta of -0, 58. Veru has a 52-week low of $4.34 and a 52-week high of $17.50. The stock has a fifty-day simple moving average of $8.54 and a 200-day simple moving average of $7.14.

Veru (NASDAQ:VERU – Get Rating) last released its results on Thursday, May 12. The company reported ($0.18) earnings per share for the quarter, missing analyst consensus estimates of ($0.16) by ($0.02). Veru had a negative return on equity of 18.64% and a negative net margin of 45.56%. In the same quarter of the previous year, the company recorded EPS of ($0.04). On average, equity analysts predict Veru will post -0.52 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently changed their positions in VERU. PNC Financial Services Group Inc. increased its stake in Veru by 833.3% in the third quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company valued at $49,000 after purchasing an additional 5,000 shares in the last quarter. Ensign Peak Advisors Inc acquired a new stake in Veru in the fourth quarter worth approximately $51,000. Josh Arnold Investment Consultant LLC bought a new stake in Veru in the fourth quarter worth approximately $59,000. Bridgefront Capital LLC acquired a new stake in Veru in the fourth quarter worth approximately $63,000. Finally, XTX Topco Ltd increased its stake in Veru by 18.7% in the first quarter. XTX Topco Ltd now owns 14,426 shares in the company valued at $70,000 after buying an additional 2,270 shares last quarter. 29.11% of the shares are currently held by institutional investors and hedge funds.

Veru Company Profile (Get an evaluation)

Veru Inc, an oncology biopharmaceutical company, is focused on the development of drugs for the management of cancers. Its commercial products include FC2 female condom/internal condom for dual protection against unwanted pregnancy and transmission of sexually transmitted infections for Ministries of Health, Government Health Agencies, UN

Featured articles

The Fly logo



Get news and reviews for Veru Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Veru and related companies with MarketBeat.com’s free daily email newsletter.